Seeking Alpha

Galapagos N.V. ADR (GLPYY)

- OTCPK - Current
  • Dec. 19, 2014, 8:09 AM
    • Galapagos NV (OTC:GLPGF) (OTCPK:GLPYY) initiates the first Phase 1 trial with GLPG1837, its investigational CFTR targeted therapy for patients with cystic fibrosis who carry class III/IV mutations. The Belgium-based study will enroll 40 healthy volunteers and will evaluate the safety, tolerability and pharmacokinetics of oral single and multiple ascending doses of GLPG1837. Results are expected in H2 2015.
    • The start of the trial triggers a $10M milestone payment from AbbVie (NYSE:ABBV).
    | Comment!
  • Dec. 16, 2014, 7:48 AM
    • Belgian biotech Galapagos NV (OTCPK:GLPYY) and Janssen Pharmaceutica NV (NYSE:JNJ) terminate their collaboration to develop the GPR84 inhibitor GLPG1205 for inflammatory bowel diseases. Full and unencumbered rights to the GPR84 program have now been transferred back to Galapagos. It plans to initiate a Phase 2 trial before the end of December.
    • The reasons for the move are not disclosed.
    | Comment!
  • Feb. 29, 2012, 5:07 AM
    Belgian drug developer Galapagos signs a deal worth up to $1.35B with Abbott Laboratories (ABT) for the development and production of an oral drug to treat arthritis and other auto-immune diseases. (PR)
    | Comment!
GLPYY vs. ETF Alternatives
Company Description
Galapagos is a midsized biotechnology company, with therapeutic programs based on proprietary disease modifying drug targets, and a focus on inflammation, orphan disease, and anti-infectives. Galapagos' approach is to develop drugs that stop or reverse a disease state using novel targets that... More
Sector: Healthcare
Country: Belgium